Product correctly added to cart.

discount label
Aprepitant β-glucuronide sodium salt
View 3D

Biosynth logo

Aprepitant β-glucuronide sodium salt

CAS: 321125-94-4

Ref. 3D-WMA12594

5mgTo inquire
10mgTo inquire
25mgTo inquire
50mgTo inquire
Estimated delivery in United States, on Thursday 23 Jan 2025

Product Information

Name:
Aprepitant β-glucuronide sodium salt
Description:

Aprepitant β-glucuronide sodium salt is a unique compound that has been shown to have potent anti-cancer properties. It works by inhibiting the cell cycle and inducing apoptosis in cancer cells. Aprepitant β-glucuronide sodium salt has been extensively studied in Chinese medicine and has shown promising results as an anticancer agent. This compound can be used to target specific proteins involved in the growth and proliferation of cancer cells, making it a highly effective treatment option for various types of tumors. Additionally, nanoparticles containing Aprepitant β-glucuronide sodium salt have been developed, which allows for targeted delivery and improved efficacy. Overall, this innovative compound holds great potential as a powerful tool in the fight against cancer.

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
534.4 g/mol
Formula:
C23H21F7N4O3
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-WMA12594 Aprepitant β-glucuronide sodium salt

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".